ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen. Dr. Berkenblit will continue with the Company through the end of August to support the transition of her responsibilities. Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer.

"Over the last eight years, Anna has played an essential role in the transformation of ImmunoGen," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "First and foremost, she led the design and execution of the pivotal development program for ELAHERE (mirvetuximab soravtansine-gynx) that culminated in FDA-accelerated approval late last year in folate receptor alpha positive platinum-resistant ovarian cancer and the unprecedented survival data reported at ASCO in June that have transformed the treatment landscape for patients with this disease. Under her leadership, we have also advanced our broader clinical pipeline of next-generation ADCs, with top-line data from our second pivotal program expected next year. In parallel, she has built and leaves us with a highly talented development organization that has cultivated deep relationships with thought leaders around the world and can rapidly deliver complex studies with high-quality data. Finally, she has been a valued colleague to me and the rest of the ImmunoGen Executive Committee. I wish Anna the very best in her future endeavors and offer my thanks for her unrelenting work on behalf of ImmunoGen, our collaborators, and most importantly, patients in need of more good days."

"I take immense pride in having been a part of the leadership team that led ImmunoGen to success with SORAYA and MIRASOL, built a clinical development team filled with top talent capable of operating effectively during a global pandemic, and contributed to the efforts that brought ELAHERE through to accelerated approval for patients with platinum-resistant ovarian cancer," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen. "It has been a pleasure and a privilege to serve this organization. As I look ahead to what's next, I look forward to spending time with my family, continuing board work with other companies, and pursuing consulting in the coming months while I watch ImmunoGen's bright future unfold."